Plazomicin: A promising novel antimicrobial in the era of bacterial resistance (Review)
Abstract
Gram-negative bacterial infections that are multidrug-resistant are on the rise and present a severe risk to patients and the general population. These infections can be challenging to treat and cause severe morbidities and multiple mortalities. A semisynthetic antimicrobial called plazomicin received approval from the US Food and Drug Administration for the treatment of adults with severe complicated urinary tract infections (cUTIs) caused by bacterial pathogens, in cases where the patients have no or limited other therapeutic options. In treating cUTIs, plazomicin has demonstrated that it is comparable to meropenem, and is a practical treatment option for outpatient antibiotic treatment settings (given intravenously, once daily, with a brief 30 min administration duration). In addition, plazomicin shows low frequency side effects including nephrotoxicity and ototoxicity. Except for the approved use of plazomicin to treat cUTIs, there is a gap in the literature regarding the role of plazomicin in therapy for patients with aggressive and life-threatening bacterial infections including Enterobacterales. Plazomicin is a reasonably expensive drug that should be used sparingly. In the present review, the molecular characteristics, chemical properties, mechanism of action, antibacterial spectrum, pharmacokinetics, clinical therapeutic indications, side effects, role in therapy and special considerations of plazomicin are discussed.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.